This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Sunshine Lake Pharma Co., Ltd.. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2026
Title: Innovations of Chao Chen in Metabolic Disease Treatment
Introduction
Chao Chen is a prominent inventor based in Dongguan, China, known for his significant contributions to the field of biotechnology. He has been instrumental in developing innovative solutions aimed at treating metabolic diseases. With a total of two patents to his name, Chen's work focuses on the creation of fusion proteins that have the potential to revolutionize clinical applications.
Latest Patents
Chao Chen's latest patents include "Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin" and "FGF21 variant, fusion protein and application thereof." The first patent describes a fusion protein that combines GLP-1 and FGF21 linked through an immunoglobulin Fc portion. This innovative protein can be substituted with analogues or variants, enhancing its stability and activity. The clinical applications of this fusion protein include reducing glucose and lipid levels, as well as body weight. The second patent focuses on a fibroblast growth factor 21 (FGF21) variant that significantly improves binding ability with targets, offering promising treatment options for metabolic diseases.
Career Highlights
Chao Chen is currently associated with Sunshine Lake Pharma Co., Ltd., where he continues to push the boundaries of research and development in the pharmaceutical industry. His work has garnered attention for its potential impact on health and wellness, particularly in managing conditions related to metabolism.
Collaborations
Chao Chen collaborates with talented individuals such as Shushan Lin and Yu Meng Li, who contribute to the innovative projects at Sunshine Lake Pharma Co., Ltd. Their combined expertise fosters a dynamic environment for groundbreaking research.
Conclusion
Chao Chen's innovative work in developing fusion proteins represents a significant advancement in the treatment of metabolic diseases. His contributions are paving the way for new therapeutic options that could improve the quality of life for many individuals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile